Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation

NCT00519896 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00519896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00519896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
September 30, 2015
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent thyroid cancer, stage iva follicular thyroid cancer, stage iva papillary thyroid cancer, stage ivb follicular thyroid cancer, stage ivb papillary thyroid cancer, stage ivc follicular thyroid cancer, stage ivc papillary thyroid cancer, thyroid gland medullary carcinoma